Why convergence matters

Convergence is one of the most powerful ideas in synthesis planning — and one of the signals SynovAI surfaces most prominently. Understanding what it means, and when to use it, changes how you read route trees.

Linear vs. convergent routes

A linear route builds the target one step at a time: A → B → C → D → target. If any step fails, the whole chain breaks.

A convergent route builds pieces in parallel and joins them near the end. Think: A → B and C → D, then B + D → target. The pieces can be made simultaneously in different flasks.

The payoff:

• Shorter elapsed time. Parallel branches run at the same time.
• Lower cumulative yield loss. Yield compounds multiplicatively down a chain (80% × 80% × 80% = 51%). Splitting into two 2-step branches and joining at the end gives each branch only 64% loss — and the losses don't compound across branches.
• Better failure tolerance. If branch A fails, branch B's work isn't wasted.

This is why the longest linear sequence (LLS) is often a better complexity measure than total step count.

What convergence badges tell you

When a molecule appears in 27 out of 27 routes, something structural is going on. It's almost certainly a key retron — a disconnection the model finds compelling, or a commercially available intermediate that cleanly closes the gap between your target and the synthon pool.

High convergence (say, ≥80% of routes) signals:

• This molecule is a good target if you want to stockpile intermediates.
• Any improvement here (better vendor, cheaper supplier, greener route to this intermediate) affects most of your options.
• There's consensus — if you override this, you're swimming against the model's prior.

Low convergence (say, ≤20% of routes) signals:

• A unique disconnection, more novel, potentially more IP-defensible.
• Higher risk — fewer alternative paths if this route fails.
• Worth investigating for patent diversity.

Using convergence in practice

The Convergence Explorer is the primary tool for this. Click any convergence badge in the route tree to see:

• Precursors — everything that feeds into this molecule
• Products — everything this molecule feeds into
• Co-occurring reactants — what reacts alongside it at the same step

This gives you the local structure of the route space around that molecule. If you find a convergence hub you want to avoid (for IP or procurement reasons), exclude it with one click and the route viewer re-filters.

The trade-off

Convergent routes trade up-front complexity (coordinating multiple parallel streams) for total elapsed time and yield. In discovery/research settings where you're making small amounts and have flexibility, highly convergent routes are often optimal. In GMP manufacturing, convergence has to be weighed against inventory holding costs and tech transfer complexity — sometimes a simpler linear route is preferable despite the theoretical efficiency loss.